Paolo Antonio Ascierto
Full Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (58)
Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7
Year:
2026
Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.
Year:
2025
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).
Year:
2025
Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes medications: 17.5 months (95%CI: 14.2 – 26.6; 77 events). B) Progression Free Survival NSCLC matched cohort; patients on any diabetes medication: 7.9 months (95%CI: 5.4 – 10.8; 113 events), patients not receiving diabetes medications: 10.1 months (95%CI: 7.7 – 13.8; 99 events). C) Overall Survival Melanoma matched cohort; patients on any diabetes medication: 22.9 months (95%CI: 12.0 – NR; 25 events), patients not receiving diabetes medications: NR months (95%CI: 28.8 – NR; 52 events). D) Progression Free Survival Melanoma matched cohort; patients on any diabetes medication: 11.4 months (95%CI: 4.9 – 23.4; 37 events), patients not receiving diabetes medications: 13.8 months (95%CI: 8.7 – 26.0; 77 events). NR: not reached; PSM: propensity score matching.
Year:
2025
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).
Year:
2025
Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
Year:
2025
Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.
Year:
2025
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving diabetes medications: 18.9 months (95%CI: 15.9-21.6; 684 events), patients on other diabetes medications/insulin therapy only: 19.3 months (95%CI: 11.6-22.9; 48 events), patients on metformin: 12.3 months (95%CI: 9.8-15.9; 100 events). B) Progression Free Survival whole cohort; patients not receiving diabetes medications: 8.2 months (95%CI: 7.1-9.4; 872 events), patients on other diabetes medications/insulin therapy only: 10.7 months (95%CI: 6.7-11.6; 61 events), patients on metformin: 7.9 months (95%CI: 5.1-10.1; 124 events).
Year:
2025
Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival whole cohort; patients on more than one diabetes medications: 15.5 months (95%CI: 11.1-20.6; 79 events), patients on one medication: 12.5 months (95%CI: 10.0 – 18.9; 69 events), patients not receiving diabetes medications: 18.9 months (95%CI: 15.9 – 21.5; 684 events). B) Progression Free Survival whole cohort; patients on more than one diabetes medications: 7.9 months (95%CI: 6.2-11.4; 101 events), patients on one medication: 8.4 months (95%CI: 4.9 – 11.9; 84 events), patients not receiving diabetes medications: 8.2 months (95%CI: 7.1 – 9.4; 872 events). Polypharmacy: more than one diabetes medication.
Year:
2025
Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (73)
caroline robert
- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse
Université de Paris Faculté de Santé
Fabio Puglisi
Head of the Unit of Medical Oncology and Cancer Prevention
-
Valentina Guarneri
Associate Professor
University of Padova
Govind Warrier
Assistant Professor of Oncology
Johns Hopkins University
Georgina V. Long
University of Sydney
Maurizio Simmaco
Full Professor Molecular Biology - Director Diparmet Diagnostic sciences
Sapienza University of Rome
Leslie A. Fecher
-
vanna chiarion sileni
Chief of Melanoma Oncology Unit
-
Umberto Malapelle
-
Edoardo Crimini
Medical Oncologist
European Institute of Oncology
Jessica C. Hassel
Heidelberg University
Massimo Di Nicola
Fondazione IRCCS Istituto Nazionale dei Tumori
James Larkin
Professor
-
Giuseppe Tonini
Full Professor of Medical Oncology
Campus Bio Medico University Hospital
Marco Gaetano Tucci
Associate Professor
University of Bari
Claus Garbe
Professor of Dermatology
Eberhard Karls Universität Tübingen
David J. Pinato
Imperial College London
Bruno Vincenzi
Professor of Medical Oncology
Università Campus Bio-Medico
Reinhard Dummer
University Hospital of Zurich
Ana Arance
University of Barcelona
Nikhil Khushalani
Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology
H Lee Moffitt Cancer Center and Research Institute
Giuseppe Giannini
Head, Unit of Advanced Molecular Diagnostic in Oncology
Sapienza University
Alexander M. Menzies
University of Sydney
Bartosz Chmielowski
Ronald Reagan UCLA Medical Center
Maria Grazia Vitale
Fondazione IRCCS Istituto Nazionale dei Tumori
Marcus Butler
University Health Network
Lucia Del Mastro
dirigente medico
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro
Sebastiano Buti
Ricercatore a contratto tipo B
University of Parma
Jean-Jacques Grob
Aix-Marseille University
Wilson H Miller Jr
McGill University
Andrea DeCensi
Director
Champalimaud Foundation
Lorenzo Nibid
Campus Bio Medico University Hospital
Cornelia Mauch
Assistant professor
university hospital of the ruhr university bochum
Giancarlo Pruneri
University of Milan
Marco Ferrari
Associate Professor
University of Padova
Helen Gogas
Head, Professor in Medical Oncology
National and Kapodistrian University of Athens
Alessio Cortellini
Imperial College London
Ignacio Melero
Kidani Professor of Cancer Immuno-Therapeutics
University of Oxford
Michael A. Postow
Weill Cornell Medical College
F. Dimitriou
Attending Physician, Head of Skin Cancer Center
University Hospital of Bern
Maria Giuseppa Vitale
-
Giuseppe Curigliano
European Institute of Oncology
Lidia Strigari
Head of Department
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Alberto Zambelli
Associate Professor
University of Milano-Bicocca
Paolo Marchetti
Sapienza University of Rome
Paul Nathan
University College London
SIMONA PISEGNA
Sapienza University of Rome
Alfredo Budillon
Chief Experimental Pharmacology Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Michele Ghidini
Docenti di ruolo di IIa fascia
University of Insubria
Francesco Pantano
National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)
Ministero dell’Istruzione, dell’Università e della Ricerca
Ryan Sullivan
Harvard University
Dirk Schadendorf
University Hospital Essen
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Grant McArthur
Lorenzo Galli Chair of Melanoma and Skin Cancers
University of Melbourne
Melissa Bersanelli
Adjunct Professor in Medical Oncology
University of Parma
Lucie Heinzerling
University Hospital
Shahneen Sandhu
-
olga nigro
Fondazione IRCCS Istituto Nazionale dei Tumori
Alessandro Russo
Humanitas University
Piotr Rutkowski
Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie
Luc Thomas
enseignant-chercheur
Centre de Recherche en Cancérologie de Lyon
Ivan Marquez-Rodas
Universidad Complutense de Madrid
Michele Maio
-
Mark Middleton
University of Oxford
MICHELE DE TURSI
ASSOCIATE PROFESSOR
University "G. d'Annunzio"
PIERFRANCO CONTE
Professore di 1^ fascia
University of Padova
Jia Xin Yu
Institute of Cancer Research
Chiara Cremolini
University Hospital of Pisa
Mario Mandalà
Associate Professor
University of Perugia
Giuseppe Perrone
Università Campus Bio-Medico di Roma
Antonio D'Alessio
King's College Hospital
Ines Pires da Silva
Medical Oncologist
University of Sydney
Luca Tagliaferri
IRCCS Researcher - Ricercatore IRCCS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Make your next move.
Prepare your application
Review drafts before you send them.